Please wait a minute...
J Zhejiang Univ (Med Sci)  2019, Vol. 48 Issue (3): 334-341    DOI: 10.3785/j.issn.1008-9292.2019.06.15
    
Research frontier of inflammatory bowel disease
FAN Yihong(),LYU Bin*()
Department of Gastroenterology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Key Laboratory for Pathophysiological Research on Digestive System Diseases of Zhejiang Province, Hangzhou 310006, China
Download: HTML( 8 )   PDF(958KB)
Export: BibTeX | EndNote (RIS)      
Key wordsInflammatory bowel diseases/epidemiology      Inflammatory bowel diseases/physiopathology      Inflammatory bowel diseases/diagnosis      Inflammatory bowel diseases/therapy      Congresses     
Received: 30 May 2019      Published: 04 September 2019
CLC:  R574.5  
Corresponding Authors: LYU Bin     E-mail: yhfansjr@163.com;lvbin@medmail.com.cn
Cite this article:

FAN Yihong, LYU Bin. Research frontier of inflammatory bowel disease. J Zhejiang Univ (Med Sci), 2019, 48(3): 334-341.

URL:

http://www.zjujournals.com/med/10.3785/j.issn.1008-9292.2019.06.15     OR     http://www.zjujournals.com/med/Y2019/V48/I3/334

Fig 1 Essential molecular players in the multistep adhesion cascade
评分项目 评分
黏膜表现  正常 0
          充血,血管纹理减少 1
          明显充血,血管纹理消失 2
          出血 3
溃疡/侵蚀大小  无 0
              <0.5 cm 1
              0.5~2 cm 2
              >2 cm 3
溃疡/侵蚀范围  无 0
              <10% 1
              10%~30% 2
              >30% 3
累及部位  不连续 < 50% 0
          连续≥50% 1
缩窄  无 0
      单发,内镜可通过 1
      多发,内镜可通过 2
      内镜不可通过 3
Tab 1 Toronto inflammatory bowel diseases global endoscopic reporting (TIGER) score[15]
Fig 2 Mammalian integrin αβ heterodimers pairing
[1]   LICHTENSTEIN G R , LOFTUS E V , ISAACS K L et al. ACG clinical guideline:management of Crohn's disease in adults[J]. Am J Gastroenterol, 2018, 113 (4): 481- 517
doi: 10.1038/ajg.2018.27
[2]   COSTA J , MAGRO F , CALDEIRA D et al. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:a systematic review and meta-analysis[J]. Inflamm Bowel Dis, 2013, 19 (10): 2098- 2110
doi: 10.1097/MIB.0b013e31829936c2
[3]   NGUYEN G C , CHONG C A , CHONG R Y . National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States[J]. J Crohns Colitis, 2014, 8 (4): 288- 295
doi: 10.1016/j.crohns.2013.09.001
[4]   XU F , LIU Y , WHEATON A G et al. Trends and factors associated with hospitalization costs for inflammatory bowel disease in the United States[J]. Appl Health Econ Health Policy, 2019, 17 (1): 77- 91
doi: 10.1007/s40258-018-0432-4
[5]   MALARCHER C A , WHEATON A G , LIU Y et al. Hospitalizations for Crohn's disease-United States, 2003-2013[J]. MMWR Morb Mortal Wkly Rep, 2017, 66 (14): 377- 381
doi: 10.15585/mmwr.mm6614a1
[6]   LIU J Z , VAN SOMMEREN S , HUANG H et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations[J]. Nat Genet, 2015, 47 (9): 979- 986
doi: 10.1038/ng.3359
[7]   BUHM H , AKIYAMA MASATO A , KYUNG-KON K et al. Amino acid position 37 of HLA-DRβ1 affects susceptibility to Crohn's disease in Asians[J]. Hum Mol Genet, 2018, 27 (22): 3901- 3910
doi: 10.1093/hmg/ddy285
[8]   HONG M , YE B D , YANG S K et al. Immunochip meta-analysis of inflammatory bowel disease identifies three novel loci and four novel associations in previously reported loci[J]. J Crohns Colitis, 2018, 12 (6): 730- 741
doi: 10.1093/ecco-jcc/jjy002
[9]   CLEYNEN I , BOUCHER G , JOSTINS L et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes:a genetic association study[J]. Lancet, 2016, 387 (10014): 156- 167
doi: 10.1016/S0140-6736(15)00465-1
[10]   PALMELA C , CHEVARIN C , XU Z et al. Adherent-invasive Escherichia coli in inflammatory bowel disease[J]. Gut, 2018, 67 (3): 574- 587
doi: 10.1136/gutjnl-2017-314903
[11]   IMAI J , KITAMOTO S , SUGIHARA K et al. Adherent-invasive Escherichia coli colonization promotes intestinal fibrosis via activation of IL-33/ST2 signaling[J]. Mucosal Immunol, 2019, 12 (3): 632- 643
doi: 10.1038/s41385-019-0138-4
[12]   PANéS J , SALAS A . Past, present and future of therapeutic interventions targeting leukocyte trafficking in inflammatory bowel disease[J]. J Crohns Colitis, 2018, 12 (suppl_2): S633- S640
doi: 10.1093/ecco-jcc/jjy011
[13]   LOBATóN T , VERMEIRE S , VAN ASSCHE G et al. Review article:anti-adhesion therapies for inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2014, 39 (6): 579- 594
doi: 10.1111/apt.12639
[14]   MACKAY C R , MACKAY I R , ROSENF S et al. T-cell function and migration-two sides of the same coin[J]. NEJM, 2000, 343:1020- 1032
doi: 10.1056/NEJM200010053431407
[15]   ZITTAN E , STEINHART A H , MILGROM R et al. Su1778-The Toronto IBD global endoscopic reporting (TIGER) score:a single, easy to use endoscopic score for all IBD patients[J]. Gastroenterology, 2019, 156 (6): Supplement 1:S- 608
[16]   LAMB C A , O'BYRNE S , KEIR M E et al. Gut-selective integrin-targeted therapies for inflammatory bowel disease[J]. J Crohns Colitis, 2018, 12 (suppl_2): S653- S668
doi: 10.1093/ecco-jcc/jjy060
[17]   FEAGAN B G , RUTGEERTS P , SANDS B E et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis[J]. N Engl J Med, 2013, 369 (8): 699- 710
doi: 10.1056/NEJMoa1215734
[18]   SANDBORN W J , FEAGAN B G , RUTGEERTS P et al. Vedolizumab as induction and maintenance therapy for Crohn's disease[J]. N Engl J Med, 2013, 369 (8): 711- 721
doi: 10.1056/NEJMoa1215739
[19]   SANDS B E , FEAGAN B G , RUTGEERTS P et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed[J]. Gastroenterology, 2014, 147 (3): 618- 627
doi: 10.1053/j.gastro.2014.05.008
[20]   VERMEIRE S , LOFTUS E V JR , COLOMBEL J F et al. Long-term efficacy of vedolizumab for Crohn's disease[J]. J Crohns Colitis, 2017, 11 (4): 412- 424
[21]   UZZAN M , TOKUYAMA M , ROSENSTEIN A et al. Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1 infected individuals[J]. Science Translational Medicine, 2018,
[22]   SANDBORN W J , FEAGAN B G , WOLF D C et al. Ozanimod induction and maintenance treatment for ulcerative colitis[J]. N Engl J Med, 2016, 374 (18): 1754- 1762
doi: 10.1056/NEJMoa1513248
[23]   FEAGAN B G , PANéS J , FERRANTE M et al. Risankizumab in patients with moderate to severe Crohn's disease:an open-label extension study[J]. Lancet Gastroenterol Hepatol, 2018, 3 (10): 671- 680
doi: 10.1016/S2468-1253(18)30233-4
[24]   PAPP K , GOTTLIEB A B , NALDI L et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR)[J]. J Drugs Dermatol, 2015, 14 (7): 706- 714
[25]   WILS P , BOUHNIK Y , MICHETTI P et al. Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients:a multicentre experience[J]. Aliment Pharmacol Ther, 2018, 47 (5): 588- 595
doi: 10.1111/apt.14487
[26]   SANDBORN W J , SU C , SANDS B E et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis[J]. N Engl J Med, 2017, 376:1723- 1736
doi: 10.1056/NEJMoa1606910
[27]   SANDBORN W J , PANNéS J , D'HAENS G R et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials[J]. Clin Gastroenterol Hepatol, 2019, 17 (8): 1541- 1550
doi: 10.1016/j.cgh.2018.11.035
[28]   LóPEZ-GARCíA A , ROVIRA M , JAUREGUI-AMEZAGA A et al. Autologous haematopoietic stem cell transplantation for refractory Crohn's disease:efficacy in a single-centre cohort[J]. J Crohns Colitis, 2017, 11 (10): 1161- 1168
doi: 10.1093/ecco-jcc/jjx054
[29]   PANéS J , GARCíA-OLMO D , VAN ASSCHEG et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease:a phase 3 randomised, double-blind controlled trial[J]. Lancet, 2016, 388 (10051): 1281- 1290
doi: 10.1016/S0140-6736(16)31203-X
[1] HU Yue, LYU Bin. Development and prospects of fecal microbiota transplantation[J]. J Zhejiang Univ (Med Sci), 2019, 48(3): 342-346.
[2] LU Zhanjun,HU Yangyang,LI Sisi,ZANG Lijuan,JIANG Weiliang,WU Jianjiong,WU Xiening,ZENG Yue,WANG Xingpeng. Anti-inflammatory effect of interleukin-35 in mice with colitis and its mechanism[J]. J Zhejiang Univ (Med Sci), 2018, 47(5): 499-506.
[3] QI Xiaohua,WANG Xinyi,HE Fan,LIU Biyao,ZHANG Tao,LI Fudong,ZHAI Yujia,LIN Junfen. Risk assessment for emergency events of infectious disease in outlying areas of large-scale activities[J]. J Zhejiang Univ (Med Sci), 2018, 47(2): 124-130.
[4] ZHENG Qi,LU Meiping. Focus on pediatric rheumatic and immune diseases[J]. J Zhejiang Univ (Med Sci), 2018, 47(2): 213-217.
[5] LU Shen,WANG Qingqing. Focus on the 14th International Symposium on Dendritic Cells[J]. J Zhejiang Univ (Med Sci), 2017, 46(1): 106-109.
[6] CHEN Xin-hua, ZHANG Xue-ming, YIN Sheng-yong, ZHENG Shu-sen. Bioelectric-technology in tumor minimally invasive therapy——from the 11th International Bioelectrics Symposium[J]. J Zhejiang Univ (Med Sci), 2015, 44(1): 108-111.
[7] Wei Jie-ping, Huang He. Highlights of the 19th Congress of Asia-Pacific Blood and Marrow Transplantation[J]. J Zhejiang Univ (Med Sci), 2015, 44(1): 112-115.
[8] WANG Kan, et al. Highlights from 1st AGA professional conference in China[J]. J Zhejiang Univ (Med Sci), 2014, 43(6): 728-730.